Journal of Diagnostics Concepts & Practice >

2022 , Vol. 21 >Issue 02: 136 - 138

DOI: https://doi.org/10.16150/j.1671-2870.2022.02.006

Expert advice

Expert suggestion for diabetes management during the recent COVID-19 pandemic

Expand
  • National Metabolic Diseases Clinical Research Center (Shanghai)

Received date: 2022-05-26

  Online published: 2022-04-25

Fold

Abstract

Recently, a new Omicron wave of coronavirus disease 2019(COVID-19) pandemic appeared in many places worldwide. Diabetes is one of the important risk factors affecting the severity including mortality of COVID-19. Optimal management of blood glucose and other metabolic parameters is crucial for patients with diabetes. Therefore, this expert′s suggestion aims at providing necessary recommendation and guidance for the comprehensive multifactorial management (from infection prevention and treatment, to metabolic control targets achievement) of diabetes patients during the current COVID-19 pandemic.

Key words： COVID-19; Omicron; Diabetes mellitus; Glycemic control

Cite this article

Chinese Society of Endocrinology,Chinese Medical Association , et al . Expert suggestion for diabetes management during the recent COVID-19 pandemic[J]. Journal of Diagnostics Concepts & Practice, 2022 , 21(02) : 136 -138 . DOI: 10.16150/j.1671-2870.2022.02.006

References

[1] 中国国家卫生健康委员会. 新型冠状病毒肺炎诊疗方案(试行第九版)[J]. 国际流行病学传染病学杂志, 2022, 49(2):73-80.
[1] China National Health Commission. Diagnosis and treatment plan for novel coronavirus pneumonia (trial version 9)[J]. Int J Epidemiol Infect Dis, 2022, 49(2):73-80.
[2] Zhang X, Zhang W, Chen S. Shanghai's life-saving efforts against the current omicron wave of the COVID-19 pandemic[J]. Lancet, 2022, 399(10340):2011-2012.
[3] Seiglie J, Platt J, Cromer SJ, et al. Diabetes as a Risk Factor for Poor Early Outcomes in Patients Hospitalized With COVID-19[J]. Diabetes Care, 2020, 43(12):2938-2944.
[4] Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study[J]. Lancet Diabetes Endocrinol, 2020, 8(10):813-822.
[5] Hartmann-Boyce J, Rees K, Perring JC, et al. Risks of and From SARS-CoV-2 Infection and COVID-19 in People With Diabetes: A Systematic Review of Reviews[J]. Diabetes Care, 2021, 44(12):2790-2811.
[6] Menni C, Valdes AM, Polidori L, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study[J]. Lancet, 2022, 399(10335):1618-1624.
[7] Yonekawa A, Shimono N. Clinical Significance of COVID-19 and Diabetes: In the Pandemic Situation of SARS-CoV-2 Variants including Omicron(B.1.1.529)[J]. Biology (Basel). 2022 Mar 4; 11(3):400.
[8] Chan JCN, Lim LL, Wareham NJ, et al. The Lancet Commission on diabetes: using data to transform diabetes care and patient lives[J]. Lancet, 2021, 396(10267):2019-2082.
[9] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华内分泌代谢杂志, 2021, 37(4):311-398.
[9] Diabetes branch of Chinese Medical Association. Guidelines for prevention and treatment of type 2 diabetes in China(2020 Edition)[J]. Chin J Endocrinol Metab, 2021, 37(4):311-398.
[10] 王卫庆, 单忠艳, 王广, 等. 新型冠状病毒肺炎疫情期间糖尿病基层管理专家建议[J]. 中华内分泌代谢杂志, 2020, 36(3):185-190.
[10] Wang WQ, Shan ZY, Wang G, et al. Expert advice on diabetes management at the grass-roots level during the outbreak of novel coronavirus pneumonia[J]. Chin J Endocrinol Metab, 2020, 36(3):185-190.
[11] 中国医师协会内分泌代谢科医师分会,中国住院患者血糖管理专家组. 中国住院患者血糖管理专家共识[J]. 中华内分泌代谢杂志, 2017, 33(1):1-10.
[11] Endocrinologist branch of Chinese Medical Association, Chinese inpatient blood glucose management expert group. Consensus of Chinese inpatient blood glucose management experts[J]. Chin J Endocrinol Metab, 2017, 33(1):1-10.
[12] Zhang Y, Wang W, Ning G. Metabolic Management Center: An innovation project for the management of metabolic diseases and complications in China[J]. J Diabetes, 2019, 11(1):11-13.
Options
Outlines

/

〈 〉